This is a StreetInsider.com Premium Only Page

Nevro (NVRO) – Company Press Releases

Apr 17, 2024 08:30 AM Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

Mar 25, 2024 08:41 AM NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization

Feb 28, 2024 04:10 PM Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw

Feb 21, 2024 04:06 PM Nevro Enters Into Cooperation Agreement With Engaged Capital

Feb 21, 2024 04:05 PM Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

Feb 1, 2024 04:30 PM Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy

Jan 29, 2024 04:30 PM Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024

Jan 18, 2024 04:15 PM Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy

Jan 17, 2024 04:15 PM Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Jan 9, 2024 08:30 AM Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results

Jan 4, 2024 04:15 PM Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nov 30, 2023 05:19 PM Nevro Announces Acquisition of Vyrsa™ Technologies

Nov 20, 2023 07:00 AM Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Nov 1, 2023 04:01 PM Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance

Oct 4, 2023 07:00 AM Nevro to Report Third Quarter 2023 Financial Results

Sep 18, 2023 07:00 AM New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy

Aug 29, 2023 06:00 AM Luca Mining and EnviroGold Global Announce MOU to Reprocess Historical Tailings at Campo Morado Mine

Aug 23, 2023 07:00 AM Nevro Announces Participation in Upcoming Investor Conferences

Aug 16, 2023 07:00 AM New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Aug 1, 2023 04:03 PM Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance

Jul 13, 2023 07:00 AM Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference

Jul 12, 2023 07:00 AM Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jun 27, 2023 07:00 AM Nevro to Report Second Quarter 2023 Financial Results

Jun 23, 2023 07:00 AM Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions

Jun 5, 2023 04:05 PM Nevro Names New Chief Commercial Officer

Jun 5, 2023 07:07 AM EnviroGold Global Closes $2.15M Financing

May 29, 2023 07:07 AM EnviroGold Global Announces $2.15M Financing

May 22, 2023 07:00 AM Nevro to Present at Jefferies Healthcare Conference

Apr 27, 2023 04:05 PM Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual

Apr 26, 2023 04:05 PM Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance

Apr 24, 2023 05:03 PM Nevro Announces Enrollment of First Patient in PDN Sensory Study

Apr 24, 2023 07:00 AM Nevro Announces Participation in Upcoming Investor Conferences

Apr 19, 2023 05:05 PM Nevro Names Kevin Thornal as New Chief Executive Officer and President

Mar 31, 2023 05:00 PM EnviroGold Global Provides Corporate Update

Mar 29, 2023 07:00 AM Nevro to Report First Quarter 2023 Financial Results

Mar 22, 2023 04:05 PM EnviroGold Global Announces Positive Preliminary Test Results & Improved Gold Recovery Rates

Mar 7, 2023 07:00 AM Nevro Announces U.S. Full Market Launch of Revolutionary HFX iQ™ Spinal Cord Stimulation System to Personalize Treatment of Chronic Pain

Feb 27, 2023 04:01 PM EnviroGold Global Provides Corporate Update

Feb 23, 2023 04:05 PM Nevro to Participate in Wells Fargo 2023 Medtech Innovation Spotlight Call Series

Feb 16, 2023 04:05 PM Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance

Feb 7, 2023 04:01 PM EnviroGold Global’s Financing is Oversubscribed at $2.8M

Feb 1, 2023 07:00 AM Nevro to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference

Jan 31, 2023 04:05 PM Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year

Jan 19, 2023 07:00 AM Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results

Jan 18, 2023 04:05 PM EnviroGold Global Announces a $2.5M Financing, Accelerating Commercialization of its Proprietary Refractory Ore Technology

Jan 12, 2023 07:00 AM Nevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual Meeting

Jan 9, 2023 06:00 AM Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance

Jan 3, 2023 06:00 AM EnviroGold Announces Commencement of Pilot Program on Hellyer Tailings with ALS Perth, and Shares for Debt Transaction

Dec 19, 2022 04:05 PM Nevro to Present at 41st Annual J.P. Morgan Healthcare Conference

Dec 14, 2022 07:00 AM Nevro Announces Two Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2023 Annual Meeting